Physician profile
Piseth Suor
NPI 1699054809
$28,241.30
in general payments reported to CMS, 2019-2025
67 companies · $6,487 in 2025
The $6,487 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,845 · 2022: $5,461 · 2023: $5,708 · 2024: $4,740 · 2025: $6,487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,756.92 |
| Education | $177.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,909.74 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,838.83 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $1,790.53 | 2021-2025 | |
| Lilly USA, LLC | $1,684.15 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $1,654.61 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,594.69 | 2021-2025 | Jardiance, Ofev, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $1,153.53 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,022.94 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,013.34 | 2021-2025 | Rexulti |
| Amgen INC. | $973.89 | 2021-2025 | Otezla, Otezla, Repatha |
| Teva Pharmaceuticals USA, INC. | $884.71 | 2021-2025 | Austedo, Austedo Xr, Uzedy |
| Pfizer INC. | $865.52 | 2021-2025 | |
| Ardelyx, INC. | $758.02 | 2024-2025 | Ibsrela |
| Gilead Sciences, INC. | $569.88 | 2022-2025 | Vemlidy, Livdelzi |
| Scilex Pharmaceuticals INC. | $533.55 | 2022-2025 | Ztlido |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Piseth Suor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.